Seeking Alpha

ACADIA Pharmaceuticals (ACAD) reopens for trade, soaring 144% following the success of its Phase...

ACADIA Pharmaceuticals (ACAD) reopens for trade, soaring 144% following the success of its Phase III trial for Pimavanserin. "Home run for them," is Jason Napodano's quick take after looking over the data. Of particular interest, he says, is the testing showed no negative impact on motor function, unlike clozapine or quetiapine.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs